Gate Bioscience and Lilly Expand Deal

Gate Bioscience expanded its research agreement with Eli Lilly to develop treatments targeting disease-causing proteins. The deal is potentially worth over $870 million and adds a new drug target to the collaboration.

Xurve View
Insights:
FILE PHOTO: The Eli Lilly logo is shown at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, U.S. June 23, 2026. REUTERS/Mike Blake/File Photo

Gate Bioscience expanded its research partnership with ELI LILLY & CO in a deal valued at more than $870M. The partnership targets disease-causing proteins through oral small-molecule drugs. The agreement builds on an initial July 2025 pact worth up to $856M.